Home Applications 218490 Application 218490
Type NDA
Sponsor ACTELION Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 OPSYNVI MACITENTAN; TADALAFIL TABLET;ORAL 10MG;20MG Yes No 002 OPSYNVI MACITENTAN; TADALAFIL TABLET;ORAL 10MG;40MG Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N218490-001 OPSYNVI MACITENTAN; TADALAFIL 10MG;20MG TABLET / ORAL RLD 2024-03-22 N218490-002 OPSYNVI MACITENTAN; TADALAFIL 10MG;40MG TABLET / ORAL RLD, RS 2024-03-22
Orange Book patents# Current patent rows page 1 of 1 · 12 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N218490-001 7094781 2025-12-05 Drug substance, Drug product 2024-04-18 N218490-001 7094781*PED 2026-06-05 Pediatric extension N218490-001 10946015 2026-09-11 U-3881 Drug product 2024-04-18 N218490-001 10946015*PED 2027-03-11 Pediatric extension N218490-001 8268847 2029-04-18 U-3882 Drug product 2024-04-18 N218490-001 8268847*PED 2029-10-18 Pediatric extension N218490-002 7094781 2025-12-05 Drug substance, Drug product 2024-04-18 N218490-002 7094781*PED 2026-06-05 Pediatric extension N218490-002 10946015 2026-09-11 U-3881 Drug product 2024-04-18 N218490-002 10946015*PED 2027-03-11 Pediatric extension N218490-002 8268847 2029-04-18 U-3882 Drug product 2024-04-18 N218490-002 8268847*PED 2029-10-18 Pediatric extension
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 8 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-11-14 07:37:17 2026-10 N218490-001 OPSYNVI 10MG;20MG TABLET / ORAL RLD 2024-03-22 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218490-002 OPSYNVI 10MG;40MG TABLET / ORAL RLD, RS 2024-03-22 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N218490-001 OPSYNVI 10MG;20MG TABLET / ORAL RLD 2024-03-22 c2088c7a36db…2026-10-15 13:18:30 2026-09 N218490-002 OPSYNVI 10MG;40MG TABLET / ORAL RLD, RS 2024-03-22 c2088c7a36db…2026-09-14 22:38:34 2026-08 N218490-001 OPSYNVI 10MG;20MG TABLET / ORAL RLD 2024-03-22 84e616aacf4f…2026-09-14 22:38:34 2026-08 N218490-002 OPSYNVI 10MG;40MG TABLET / ORAL RLD, RS 2024-03-22 84e616aacf4f…2026-08-18 06:07:40 2026-07 N218490-001 OPSYNVI 10MG;20MG TABLET / ORAL RLD 2024-03-22 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218490-002 OPSYNVI 10MG;40MG TABLET / ORAL RLD, RS 2024-03-22 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N218490-001 OPSYNVI 10MG;20MG TABLET / ORAL RLD 2024-03-22 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N218490-002 OPSYNVI 10MG;40MG TABLET / ORAL RLD, RS 2024-03-22 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N218490-001 OPSYNVI 10MG;20MG TABLET / ORAL RLD 2024-03-22 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N218490-002 OPSYNVI 10MG;40MG TABLET / ORAL RLD, RS 2024-03-22 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N218490-001 OPSYNVI 10MG;20MG TABLET / ORAL RLD 2024-03-22 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N218490-002 OPSYNVI 10MG;40MG TABLET / ORAL RLD, RS 2024-03-22 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N218490-001 OPSYNVI 10MG;20MG TABLET / ORAL RLD 2024-03-22 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N218490-002 OPSYNVI 10MG;40MG TABLET / ORAL RLD, RS 2024-03-22 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N218490-001 OPSYNVI 10MG;20MG TABLET / ORAL RLD 2024-03-22 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N218490-002 OPSYNVI 10MG;40MG TABLET / ORAL RLD, RS 2024-03-22 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N218490-001 OPSYNVI 10MG;20MG TABLET / ORAL RLD 2024-03-22 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N218490-002 OPSYNVI 10MG;40MG TABLET / ORAL RLD, RS 2024-03-22 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N218490-001 OPSYNVI 10MG;20MG TABLET / ORAL RLD 2024-03-22 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N218490-002 OPSYNVI 10MG;40MG TABLET / ORAL RLD, RS 2024-03-22 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N218490-001 OPSYNVI 10MG;20MG TABLET / ORAL RLD 2024-03-22 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N218490-002 OPSYNVI 10MG;40MG TABLET / ORAL RLD, RS 2024-03-22 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N218490-001 OPSYNVI 10MG;20MG TABLET / ORAL RLD 2024-03-22 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N218490-002 OPSYNVI 10MG;40MG TABLET / ORAL RLD, RS 2024-03-22 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N218490-001 OPSYNVI 10MG;20MG TABLET / ORAL RLD 2024-03-22 d06236e962d9…2024-10-29 15:01 UTC 2024-10 N218490-002 OPSYNVI 10MG;40MG TABLET / ORAL RLD, RS 2024-03-22 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N218490-001 OPSYNVI 10MG;20MG TABLET / ORAL RLD 2024-03-22 79d66fd596c7…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N218490-002 OPSYNVI 10MG;40MG TABLET / ORAL RLD, RS 2024-03-22 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N218490-001 OPSYNVI 10MG;20MG TABLET / ORAL RLD 2024-03-22 301d65b070ca…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N218490-002 OPSYNVI 10MG;40MG TABLET / ORAL RLD, RS 2024-03-22 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N218490-001 OPSYNVI 10MG;20MG TABLET / ORAL RLD 2024-03-22 1e350fbaab3a…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N218490-002 OPSYNVI 10MG;40MG TABLET / ORAL RLD, RS 2024-03-22 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 N218490-001 OPSYNVI 10MG;20MG TABLET / ORAL RLD 2024-03-22 8072bd15b7f6…2024-05-31 18:47 UTC 2024-05 N218490-002 OPSYNVI 10MG;40MG TABLET / ORAL RLD, RS 2024-03-22 8072bd15b7f6…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N218490-001 OPSYNVI 10MG;20MG TABLET / ORAL RLD 2024-03-22 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N218490-002 OPSYNVI 10MG;40MG TABLET / ORAL RLD, RS 2024-03-22 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 4 · 156 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N218490-001 7094781 2025-12-05 Drug substance, Drug product 2024-04-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218490-001 7094781*PED 2026-06-05 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218490-001 10946015 2026-09-11 U-3881 Drug product 2024-04-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218490-001 10946015*PED 2027-03-11 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218490-001 8268847 2029-04-18 U-3882 Drug product 2024-04-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218490-001 8268847*PED 2029-10-18 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218490-002 7094781 2025-12-05 Drug substance, Drug product 2024-04-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218490-002 7094781*PED 2026-06-05 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218490-002 10946015 2026-09-11 U-3881 Drug product 2024-04-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218490-002 10946015*PED 2027-03-11 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218490-002 8268847 2029-04-18 U-3882 Drug product 2024-04-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218490-002 8268847*PED 2029-10-18 Pediatric extension d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N218490-001 7094781 2025-12-05 Drug substance, Drug product 2024-04-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N218490-001 7094781*PED 2026-06-05 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N218490-001 10946015 2026-09-11 U-3881 Drug product 2024-04-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N218490-001 10946015*PED 2027-03-11 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N218490-001 8268847 2029-04-18 U-3882 Drug product 2024-04-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N218490-001 8268847*PED 2029-10-18 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N218490-002 7094781 2025-12-05 Drug substance, Drug product 2024-04-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N218490-002 7094781*PED 2026-06-05 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N218490-002 10946015 2026-09-11 U-3881 Drug product 2024-04-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N218490-002 10946015*PED 2027-03-11 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N218490-002 8268847 2029-04-18 U-3882 Drug product 2024-04-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N218490-002 8268847*PED 2029-10-18 Pediatric extension c2088c7a36db…2026-09-14 22:38:34 2026-08 N218490-001 7094781 2025-12-05 Drug substance, Drug product 2024-04-18 84e616aacf4f…2026-09-14 22:38:34 2026-08 N218490-001 7094781*PED 2026-06-05 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N218490-001 10946015 2026-09-11 U-3881 Drug product 2024-04-18 84e616aacf4f…2026-09-14 22:38:34 2026-08 N218490-001 10946015*PED 2027-03-11 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N218490-001 8268847 2029-04-18 U-3882 Drug product 2024-04-18 84e616aacf4f…2026-09-14 22:38:34 2026-08 N218490-001 8268847*PED 2029-10-18 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N218490-002 7094781 2025-12-05 Drug substance, Drug product 2024-04-18 84e616aacf4f…2026-09-14 22:38:34 2026-08 N218490-002 7094781*PED 2026-06-05 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N218490-002 10946015 2026-09-11 U-3881 Drug product 2024-04-18 84e616aacf4f…2026-09-14 22:38:34 2026-08 N218490-002 10946015*PED 2027-03-11 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N218490-002 8268847 2029-04-18 U-3882 Drug product 2024-04-18 84e616aacf4f…2026-09-14 22:38:34 2026-08 N218490-002 8268847*PED 2029-10-18 Pediatric extension 84e616aacf4f…2026-08-18 06:07:40 2026-07 N218490-001 7094781 2025-12-05 Drug substance, Drug product 2024-04-18 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218490-001 7094781*PED 2026-06-05 Pediatric extension caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218490-001 10946015 2026-09-11 U-3881 Drug product 2024-04-18 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218490-001 10946015*PED 2027-03-11 Pediatric extension caaa826d4ba7…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 3 · 104 observed states.
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join OPSYNVI MACITENTAN AND TADALAFIL Actelion Pharmaceuticals US, Inc. 6945b183-18d3-40de-afd1-c88e33cc1a63 2025-04-11 Boxed warning, Warnings, Adverse reactions Exact identifier application applno (NDA): 218490 application number: NDA218490
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Documents# Document, Submission type, Date table Document Submission type Date 81891 SUPPL 2025-04-08 81822 SUPPL 2025-04-03 80567 SUPPL 2024-12-13 79983 ORIG 2024-10-25 77958 ORIG 2024-03-25 77957 ORIG 2024-03-25 77953 ORIG 2024-03-25